
Moderna Inc (NASDAQ:MRNA) is trading higher Monday after the U.S. Food and Drug Administration approved the Biologics License Application for SPIKEVAX to prevent COVID-19 in individuals 18 years of age and older.
SPIKEVAX, the company's mRNA Covid-19 vaccine, has now received approval from regulators in more than 70 countries. The vaccine was previously available under Emergency Use Authorization in the U.S.